Inovio Pharmaceuticals Inc (NYSEMKT:INO) on Feb. 27 announced the pricing of an underwritten public offering of 18,966,000 shares of common stock for a public offering price of $2.90 per share. The gross proceeds to Inovio from this offering are expected to be approximately $55 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was 7.90% in last session and finished the day at $3.55. Traded volume was 13,674,500 million shares in the last session and the average volume of the stock remained 6.50 million shares. The beta of the stock remained 3.55. Inovio Pharmaceuticals Inc (NYSEMKT:INO) insider ownership is 0.30%.

Shares of Dendreon Corp. (NASDAQ:DNDN) saw unusually large options trading activity on Monday. Stock investors purchased 6,345 put options on the stock, American Banking and Market News reports. Dendreon Corporation (NASDAQ:DNDN) rose percent to $14.93 yesterday on volume of 25.95 million shares. The intra-day range of the stock was $3.11 to $3.46. Dendreon Corporation (NASDAQ:DNDN) has a market capitalization of $521.28 million.

Oppenheimer began coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research note issued to investors on Friday, TheFlyOnTheWall.com reports. The firm issued a market perform rating on the stock. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s stock on Mar 3, 2014 reported a increase of 6.16% to the closing price of $12.41. Its fifty two weeks range is $1.12 -$13.33. The total market capitalization recorded $733.32 million. The overall volume in the last trading session was 25,909,652 million shares. In its share capital, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has 152.25 million outstanding shares.

Dyax Corp. (NASDAQ:DYAX) CMO Burt A. Adelman sold 55,000 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $9.68, for a total transaction of $532,400.00. On Monday, shares of Dyax Corp. (NASDAQ:DYAX) advanced 6.62% to close the day at $10.31. Company return on investment (ROI) is -67.60% and its monthly performance is recorded as 21.44%. Dyax Corp. (NASDAQ:DYAX) quarterly revenue growth is 25.73%.